Correlation between metastatic lymph node ratio and prognosis in patients with extrahepatic cholangiocarcinoma

Table 1 Clinicopathologic factors and prognosis

Clinicopathologic factors	No. of patients	Survival (%)		P valuea
		3-yr	5-yr
Total cases	78	47.26	23.99
Age (yr)				0.388
≤ 60	46	57.14	28.57
> 60	32	45.22	26.65
Sex				0.748
Male	51	46.92	21.90
Female	27	48.48	36.36
Duration of surgery (min)				0.763
≤ 300	41	46.27	27.76
> 300	37	47.98	18.66
Intraoperative blood loss (mL)				0.337
≤ 500	47	57.14	28.57
> 500	31	46.34	26.42
Differentiation degree				< 0.01
Highly	24	61.32	33.45
Moderately	44	50.00	28.04
Poorly	10	23.08	15.38
Perineural invasion				0.435
Yes	57	38.72	14.75
No	21	68.38	48.84
Tumor embolism				0.183
Yes	3	33.33	33.33
No	75	47.94	25.68
T stage				0.369
T1	2	100	50
T2	7	53.07	33.77
T3	24	46.05	21.98
T4	45	37.40	18.70
Total number of lymph node dissected				0.179
≤ 15	30	45.92	26.53
> 15	48	39.39	26.26
Lymph node metastasis				0.010
Yes	55	37.74	17.56
No	23	70.13	28.59
MLNR				0.002
0	23	70.13	28.59
0-0.2	12	54.01	21.60
0.2-0.5	18	48.34	18.84
> 0.5	25	33.67	10.03
TNM stage				0.044
I	2	54.83	27.95
II	26	41.67	21.03
III	50	35.06	17.53
Cutting edge				0.043
Negative	75	54.36	25.02
Positive	3	33.33	10.00
Postoperative chemotherapy				0.055
Yes	64	54.55	22.02
No	14	46.80	22.40

^aLog-rank test. MLNR: Metastatic lymph node ratio; TNM: Tumor-node-metastasis.

Table 2 Multivariate analysis for predictive factors of extrahepatic cholangiocarcinoma patient survival

Factors	β	SD	χ2	P value	HR	95%CI
MLNR	0.75	0.19	15.01	< 0.01	2.13	1.45–3.11
TNM stage	0.67	0.26	6.55	0.011	1.97	1.17–3.31

MLNR: Metastatic lymph node ratio; TNM: Tumor-node-metastasis.